Meta Pharmaceuticals receives FDA rare pediatric disease designation for META-001-PH

ByShawn M. Carter

Fact checked byMindy Valcarcel, MS

Key takeaways:

META-001-PH is intended to treat primary hyperoxaluria.
The designation is designed to facilitate drug and biologics development for pediatric diseases.

Meta Pharmaceuticals has received FDA rare pediatric disease designation for its investigational new drug META-001-PH, according to a press release.

META-001-PH is intended for the treatment of primary hyperoxaluria, according to the release.

Generic FDA News infographic — META-001-PH is intended for the treatment of primary hyperoxaluria, the release noted. *Image: Adobe Stock.*

The rare pediatric disease tag is designed to facilitate drug and biologics development for pediatric diseases that affect fewer than 200,000 people in the United States, and which occur primarily in patients aged younger than 18 years.

Reference:

META Pharmaceuticals announces FDA grants rare pediatric disease designation to META-001-PH for the treatment of primary hyperoxaluria. Available at:http://en.metabiopharma.com/index.php/2024/08/06/meta_pharmaceuticals_announces_fda_grants_rare_pediatric_disease_designation_to_meta-001-ph_for_the/. Published Aug. 6, 2024. Accessed Aug. 7, 2024.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Meta Pharmaceuticals receives FDA rare pediatric disease designation for META-001-PH

Key takeaways:

Reference:

Related Content